Name: OKYO PHARMA LTD (OKYO) Stock
Brand: OKYO PHARMA LTD
Rating: 4 (3 reviews)

OKYO Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

2 days ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

5 days ago - By: OKYO Pharma LTD

OKYO Pharma to Present at OIS XV in San Diego

5 days ago - By: OKYO Pharma LTD

OKYO Pharma to Present at OIS XV in San Diego

2 months ago - By: Stocktwits

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

5 months ago - By: ACCESS Newswire

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

25 days ago - By: OKYO Pharma LTD

OKYO Pharma to Present at BIO-Europe 2025 in Vienna

a month ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

a month ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

2 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

2 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

4 months ago - By: Benzinga - Mentions: HBIO SRPT MEIP WINT ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

4 months ago - By: Benzinga - Mentions: SSY SRPT CUE PDSB ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

4 months ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

6 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

6 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

7 months ago - By: OKYO Pharma LTD

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

7 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

7 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

8 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

8 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

9 months ago - By: OKYO Pharma LTD